ArticlesOnce daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial
Introduction
Chronic obstructive pulmonary disease (COPD) is seen worldwide. The frequency of COPD and number of resulting deaths continues to increase.1, 2 Since patients with COPD have one to four acute exacerbations a year, and many of them have to be admitted, the economic burden of this disease is very high.3 In the USA, about US$7 billion are attributable to direct costs, and US$8 billion to loss of productivity.4 Among patients requiring treatment in hospital, 20–60% will need endotracheal intubation and admission to an intensive-care unit (ICU) with a median cost of hospital stay of US$7400 per patient (range 4100–16000).2, 5
Although most guidelines recommend antibiotics for patients with acute exacerbations of COPD, the fundamental question about their effectiveness remains unanswered. Most studies are not placebo-controlled trials—mainly done for new product registration—and they are unlikely to be valuable in assessment of the role of antibiotics in the treatment of acute exacerbation of COPD.6, 7, 8, 9, 10, 11 Of nine placebo-controlled trials included in one meta-analysis,12 five did not show a significant benefit in the group treated with antibiotics. The overall results favoured antibiotics, but the benefit was clinically unimportant. Although inpatients seemed to benefit more from antibiotics than outpatients, extrapolation of the marginal effect seen in this meta-analysis12 to severely ill patients, such as those managed in ICUs, might be hazardous. Nonetheless, use of antibiotics in severely ill patients with COPD requiring mechanical ventilation remains usual practice, although this treatment is not yet evidence based. Whether antibiotic treatment is effective in severely ill patients with COPD requiring mechanical ventilation is, indeed, an issue that has not been well investigated. The few data in this specialty, and current concern about use of antibiotics and their contribution to selection of resistant bacteria, show that a placebo-controlled study is needed.
Choice of antimicrobial agent is another difficult clinical decision when antibiotic treatment is considered. Indeed, conventional first-line agents—including ampicillin, amoxicillin, doxycycline, and trimethoprim-sulfa-methoxazole—were associated with a low number of treatment failures in early studies.6, 7, 13 However, the increasing proportion of resistant respiratory pathogens to these antibiotics prompted evaluation of new agents, such as fluoroquinolones.14, 15, 16 The susceptibility of common respiratory pathogens to fluoroquinolones, and the good pharmacokinetic characteristics of these antibiotics, is shown in the favourable outcome rate compared with traditional agents.8, 9, 10, 11, 17 However, most therapeutic trials with fluoroquinolones have been done in moderate exacerbations of COPD, and little is known about the usefulness of these drugs in patients with severe COPD.
We therefore designed a randomised, placebo-controlled clinical trial to assess the efficacy of oral ofloxacin in the treatment of patients admitted to the ICU for severe acute exacerbation of COPD requiring mechanical ventilation.
Section snippets
Patients
From January, 1996, to December, 1999, consecutive patients aged 40 years or older, who were admitted to the medical ICUs of Fattouma Bourguiba Hospital (Monastir, Tunisia) and Farhat Hached Hospital (Sousse, Tunisia) for acute exacerbation of COPD, were included in the study. Patients were eligible if they were admitted to the ICU with acute exacerbation of COPD—diagnosed on the basis of clinical history, physical examination, and chest radiograph—and had an acute respiratory failure requiring
Results
From January, 1996, to December, 1999, 213 patients with COPD were admitted to one of the two participating ICUs with acute respiratory failure; 120 patients (56%) were excluded from the trial before randomisation (figure 1). The most common reasons for exclusion were pneumonia, antibiotic treatment at admission to ICU, and serious comorbidity. Of the 93 participants randomly assigned, three were removed (two on ofloxacin and one on placebo) because they required non-invasive ventilation for
Discussion
Our results show that in patients with severe acute exacerbation of COPD requiring mechanical ventilation, 400 mg ofloxacin given enterally once daily reduced the mortality rate in hospital and the need for additional antibiotic therapy. Duration of mechanical ventilation and length of hospital stay were also shortened. Our data lend support to the clinical benefit of antibiotic administration to patients with severe acute exacerbation of COPD requiring mechanical ventilation, and show that
References (27)
Epidemiology and treatment of chronic bronchitis and its exacerbations
Chest
(1995)- et al.
A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis
Chest
(1998) Trends in anti-microbiol susceptibility of bacterial pathogens of the respiratory tract
Am J Med
(1995)Do bacteria cause exacerbations of COPD?
Chest
(2000)- et al.
The role of bacteria in exacerbations of COPD: a constructive view
Chest
(2000) - et al.
Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease
JAMA
(1995) Acute exacerbation of COPD: how to evaluate severity and treat the underlying cause
Postgrad Med
(1992)National Hospital Discharge Survey, 1991: National Center for Health Statistics
Vital Health Stat
(1994)- et al.
Outcomes following acute exacerbation of severe chronic obstructive lung disease
Am J Respir Crit Care Med
(1996) Single-blind comparative trial of trimethoprim-sulfamethoxazole and ampicillin in the treatment of exacerbations of chronic bronchitis
BMJ
(1969)
Comparative trials of doxycycline versus amocxicillin, cephalexin and enoxacin in bacterial infections in chronic bronchitis and asthma
Scand J Infect Dis
Efficacy of oral ciprofloxacin vs clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis
Clin Infect Dis
Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily
Antimicrob Agents Chemother
Cited by (242)
COPD patient profiles in primary care. Referral criteria
2024, SemergenInteraction of sodium dodecyl sulfate and triton X-100 with ofloxacin drug using conductivity and UV–visible spectroscopic techniques in aqueous alcohols media at several temperatures
2024, Colloids and Surfaces A: Physicochemical and Engineering AspectsSpanish COPD Guidelines (GesEPOC) 2021 Update Diagnosis and Treatment of COPD Exacerbation Syndrome
2022, Archivos de BronconeumologiaShort- Versus Standard-Course Nonmacrolide Antibiotic Treatment in Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Retrospective, Observational Cohort Study
2021, Clinical TherapeuticsCitation Excerpt :Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) significantly contribute to disease morbidity and mortality and are precipitated by infection with bacterial pathogens in up to 50% of cases.1,2 Antibiotics are often prescribed in this population, although their precise role remains controversial.1–7 Severity of illness, frequency of exacerbations, prior antibiotic exposure, and the limited diagnostic utility of microbiologic testing may influence antibiotic selection in AECOPD.3–6